Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 701-368-1
CAS number: 1962138-75-5
1: Distribution of LA35S in urine and feces after administration of
single dose of various quantities by stomach tube (Michael, 1968)
Average of 3 animals
Average of 5 animals
2: Disposition of 3% in bile duct ligated rats 90 hours after a single
dose of LAS (Michael, 1968).
The purpose of the study was to determine
the absorption, distribution and metabolic fate of test substance,
C10-13 LAS in rats.
Charles river male rats (150-200 g) were
used in this study. The rats were housed in individual
cages which permitted the separate collection of urine and feces. For
the determination of disposition profile of chemical, rats were fasted
for 16 hours and given orally an aqueous solution containing LA35S. The
dose was given in 1.0 mL volume. The urine and feces were collected
daily for examination. At the termination of the study, the animals were
killed, and selected organs and tissues were taken for radioassay.
The absorption, route of absorption and
enterohepatic circulation of test substance were also quantified in the
study. The route of absorption was determined by oral
feeding of 40 mg of LAS to thoracic duct-cannulated rats. The lymph was
collected from each animal in a single 42-hour fraction. For absorption
study, each rat received orally 1.2 mg of test substance. The urine and
feces of each animal were collected for 90 hours after dosing for
The enterohepatic circulation of the
surfactant was quantified by using a dual rat study. In this, Rat A of
one pair received 1.2 mg of LAS by stomach tube, while Rat A of second
pair received another chemical. The 35S containing compounds from LA35S
that were excreted in bile of Rat A and transferred by cannula to Rat B
were completely absorbed from the gastrointestinal tract of Rat B, and
nearly two-thirds of this activity was excreted in the bile of Rat B.
For the excretion study, the cumulative
excretion of LA35S, at dose levels 0.6, 1.2, 8.0 and 40.0 mg over a 3-
day period following a single administration is determined.
Urine and feces samples were also analyzed
for the identification of metabolites. Various analytical techniques
like column chromatography, infrared, nuclear magnetic resonance (NMR),
and mass spectra were used for the determination of metabolites.
The results revealed 80-90% of the
administered dose was readily absorbed from the gastrointestinal tract
and excreted primarily through urine. Of the absorbed LA35S, 60-65 % was
excreted in the urine as a mixture of sulfo - phenyl butanoic and
sulfophenyl pentanoic acids. 35% of the absorbed 35S was excreted in the
bile and was reabsorbed completely from the gastrointestinal tract. Very
little was found in the lymph, so transport of LAS is probably by way of
portal venous blood.
Based on the above, LAS was readily absorbed
by the gastrointestinal tract, rapidly metabolized and excreted in the
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Do not show this message again